Not a Member? Register Now
Email this page
Send the page "" to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
FDA Date: 05/22/2017
Saxenda (liraglutide) Injection REMS
Goal of the Saxenda (liraglutide) Injection REMS Program
The goal of the SAXENDA REMS is to mitigate the potential risk of medullary thyroid carcinoma and the risk of acute pancreatitis (including necrotizing pancreatitis) associated with SAXENDA by:• Informing healthcare providers about the potential risk of medullary thyroid carcinoma associated with SAXENDA
• Informing healthcare providers about the risk of acute pancreatitis (including necrotizing pancreatitis) associated with SAXENDA
• Communication Plan